ATE534649T1 - Imidazothiazole und imidazoxazolderivative als inhibitoren von p38 - Google Patents

Imidazothiazole und imidazoxazolderivative als inhibitoren von p38

Info

Publication number
ATE534649T1
ATE534649T1 AT04752390T AT04752390T ATE534649T1 AT E534649 T1 ATE534649 T1 AT E534649T1 AT 04752390 T AT04752390 T AT 04752390T AT 04752390 T AT04752390 T AT 04752390T AT E534649 T1 ATE534649 T1 AT E534649T1
Authority
AT
Austria
Prior art keywords
imidazoxazole
imidazothiazoles
inhibitors
derivatives
inhibiting
Prior art date
Application number
AT04752390T
Other languages
English (en)
Inventor
Mark Ashwell
Syed Ali
Jifeng Liu
Yanbin Liu
Peter Lohse
Belew Mekonnen
Robert Selliah
Manish Tandon
Woj Wrona
Valery Antonenko
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE534649(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arqule Inc filed Critical Arqule Inc
Application granted granted Critical
Publication of ATE534649T1 publication Critical patent/ATE534649T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
AT04752390T 2003-05-15 2004-05-14 Imidazothiazole und imidazoxazolderivative als inhibitoren von p38 ATE534649T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47073503P 2003-05-15 2003-05-15
US51229803P 2003-10-17 2003-10-17
PCT/US2004/015368 WO2004110990A2 (en) 2003-05-15 2004-05-14 Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38

Publications (1)

Publication Number Publication Date
ATE534649T1 true ATE534649T1 (de) 2011-12-15

Family

ID=33555294

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04752390T ATE534649T1 (de) 2003-05-15 2004-05-14 Imidazothiazole und imidazoxazolderivative als inhibitoren von p38

Country Status (9)

Country Link
US (2) US7902192B2 (de)
EP (2) EP1633758B1 (de)
JP (1) JP4939220B2 (de)
KR (1) KR20060025141A (de)
AT (1) ATE534649T1 (de)
AU (1) AU2004247626B8 (de)
CA (1) CA2526285A1 (de)
MX (1) MXPA05012377A (de)
WO (1) WO2004110990A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
JP4939220B2 (ja) 2003-05-15 2012-05-23 アークル インコーポレイテッド ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体
MY143245A (en) * 2004-04-28 2011-04-15 Mitsubishi Tanabe Pharma Corp 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases
WO2006044869A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
US7872017B2 (en) * 2006-05-19 2011-01-18 Abbott Laboratories Fused bicycloheterocycle substituted azabicyclic alkane derivatives
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
KR20100024494A (ko) 2007-06-22 2010-03-05 아르퀼 인코포레이티드 퀴나졸리논 화합물 및 이의 사용 방법
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
CN101821247A (zh) 2007-10-12 2010-09-01 艾科尔公司 作为hsp90抑制剂的抗癌用5-(2-羟基苯基)四唑化合物
US8067409B2 (en) * 2007-11-27 2011-11-29 Abbott Laboratories Protein kinase inhibitors
CA2744713A1 (en) 2008-12-05 2010-06-10 Arqule, Inc. Raf inhibitors and their uses
NZ596123A (en) * 2009-05-19 2014-08-29 Dow Agrosciences Llc Compounds and methods for controlling fungi
GB201321731D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US11332479B2 (en) 2016-07-05 2022-05-17 Korea Institute Of Science And Technology Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same
KR101948805B1 (ko) 2016-07-05 2019-02-15 한국과학기술연구원 항종양 효과를 갖는 이미다조옥사졸 유도체 및 이를 포함하는 약학적 조성물
KR20200115620A (ko) 2018-01-29 2020-10-07 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
JP7229257B2 (ja) * 2018-01-29 2023-02-28 メルク パテント ゲーエムベーハー Ｇｃｎ２阻害剤およびその使用
EP3845539B1 (de) * 2019-12-31 2022-11-16 Korea Institute of Science and Technology Imidazooxazolderivat mit antitumorwirkung und pharmazeutische zusammensetzung damit
WO2025101004A1 (ko) * 2023-11-08 2025-05-15 한양대학교 에리카산학협력단 6-aryl imidazo[2,1-b]thi/oxazole-2-carboxilic acid 유도체 및 이를 유효성분으로 함유하는 알츠하이머병 치료용 약학 조성물

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455924A (en) 1967-02-08 1969-07-15 Upjohn Co Dianisylimidazoles
JPS61214793A (ja) 1985-03-15 1986-09-24 Citizen Watch Co Ltd Ｆｄｄ駆動用サ−ボ制御回路
US4794114A (en) 1986-08-19 1988-12-27 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
US4892578A (en) 1987-11-06 1990-01-09 Fmc Corporation Phenylmethyl-4,4-dimethyl-3-isoxazolidinone plant regulators
JPH05503919A (ja) * 1989-06-13 1993-06-24 スミスクライン・ビーチャム・コーポレイション 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制
AU7629594A (en) 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
ATE186551T1 (de) 1993-09-17 1999-11-15 Smithkline Beecham Corp Medikamente bindendes protein
US5869043A (en) 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
US5783664A (en) 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
US6090626A (en) 1994-05-31 2000-07-18 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of raf gene expression
US6410518B1 (en) 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU2092597A (en) 1996-03-07 1997-09-22 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
CA2250232A1 (en) 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6376214B1 (en) 1997-02-18 2002-04-23 Smithkline Beecham Corporation DNA encoding a novel homolog of CSBP/p38 MAP kinase
US6344476B1 (en) 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
JP2002500650A (ja) 1997-05-23 2002-01-08 バイエル、コーポレイション Ｒａｆキナーゼ阻害剤
US5994412A (en) 1997-07-10 1999-11-30 Merck & Co., Inc. Bis-aryl ethers, compositions containing such compounds and methods of treatment
PL340412A1 (en) 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
DE69834842T2 (de) 1997-12-22 2007-05-10 Bayer Pharmaceuticals Corp., West Haven Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen
EP1449834A3 (de) 1997-12-22 2004-12-22 Bayer Corporation Hemmung der RAF-Kinase unter Verwendung von symmetrisch und unsymmetrisch substituierten Harnstoffen
EP1047418B1 (de) 1997-12-22 2005-07-27 Bayer Pharmaceuticals Corp. Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6162613A (en) 1998-02-18 2000-12-19 Vertex Pharmaceuticals, Inc. Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
IL141724A0 (en) 1998-08-28 2002-03-10 Scios Inc INHIBITORS OF P38-α KINASE
AR023659A1 (es) 1998-09-18 2002-09-04 Vertex Pharma Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
AU3114600A (en) 1998-12-16 2000-07-03 Vertex Pharmaceuticals Incorporated Crystallized p38 complexes
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (de) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
CN1310906C (zh) 1999-05-21 2007-04-18 肖斯公司 用作p38激酶抑制剂的吲哚类型的衍生物
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
EP1299388B1 (de) 2000-07-11 2009-05-13 Pharma Mar, S.A. Variolinderivate als antikrebsmittel
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE304009T1 (de) 2001-04-04 2005-09-15 Pfizer Prod Inc Neue benzotriazole mit entzündungshemmender wirkung
MXPA03009000A (es) 2001-04-13 2004-02-12 Boehringer Ingelheim Pharma Compuestos benzo-fusionados 1,4-disustituidos.
US20030207914A1 (en) 2001-04-20 2003-11-06 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2443950C (en) 2001-04-20 2011-10-18 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US7196095B2 (en) * 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
GB0124848D0 (en) 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
ATE345130T1 (de) 2001-12-03 2006-12-15 Bayer Pharmaceuticals Corp Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
AU2002365899B2 (en) 2001-12-04 2007-09-13 Onyx Pharmaceuticals, Inc. RAF-MEK-ERK pathway inhibitors to treat cancer
US20030207872A1 (en) 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US20040023961A1 (en) 2002-02-11 2004-02-05 Bayer Corporation Aryl ureas with raf kinase and angiogenisis inhibiting activity
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
US7071216B2 (en) 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
AU2003224257A1 (en) 2002-04-09 2003-10-27 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
WO2003102139A2 (en) 2002-05-29 2003-12-11 Uab Research Foundation Erbin as a negative regulator of ras-raf-erk signaling
CA2494824A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
US7476683B2 (en) 2002-08-27 2009-01-13 Merck Patent Gmbh Glycinamide derivatives as raf-kinase inhibitors
EP1562905A2 (de) 2002-10-24 2005-08-17 MERCK PATENT GmbH Methylenharnstoffderivate als raf-kinase inhibitoren
PT1847539E (pt) 2002-12-24 2009-10-06 Astrazeneca Ab Derivados de quinazolina
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2518530A1 (en) 2003-03-11 2004-09-23 Novartis Ag Use of isoquinoline derivatives for treating cancer and map kinase related diseases
MXPA05010020A (es) 2003-03-24 2005-11-17 Merck Patent Gmbh Derivados de oxamida.
US20070129281A1 (en) 2003-04-02 2007-06-07 Carr Robin A E Pharmaceutical compounds
GB0308511D0 (en) 2003-04-14 2003-05-21 Astex Technology Ltd Pharmaceutical compounds
JP4939220B2 (ja) 2003-05-15 2012-05-23 アークル インコーポレイテッド ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体
EP1670787B1 (de) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokininhibitoren
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
WO2006044869A1 (en) 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
CN101115761B (zh) 2005-01-19 2012-07-18 里格尔药品股份有限公司 2,4-嘧啶二胺化合物的前药及其应用
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
GB0609621D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate

Also Published As

Publication number Publication date
JP2006528983A (ja) 2006-12-28
AU2004247626B2 (en) 2011-01-20
MXPA05012377A (es) 2006-05-25
AU2004247626B8 (en) 2011-05-19
US20070270418A1 (en) 2007-11-22
US20110301160A1 (en) 2011-12-08
EP1633758B1 (de) 2011-11-23
JP4939220B2 (ja) 2012-05-23
CA2526285A1 (en) 2004-12-23
WO2004110990A3 (en) 2005-03-24
EP1633758A2 (de) 2006-03-15
EP2251343A1 (de) 2010-11-17
AU2004247626A1 (en) 2004-12-23
WO2004110990A2 (en) 2004-12-23
KR20060025141A (ko) 2006-03-20
US7902192B2 (en) 2011-03-08

Similar Documents

Publication Publication Date Title
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
DE60334651D1 (de) Nicotinamide und deren Verwendung als P38 Inhibitoren
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
ATE521608T1 (de) Glucokinaseaktivatoren
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
NO20013341D0 (no) Fenylfenantridiner med PDE-IV inhiberende aktivitet
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
EP1481077A4 (de) Mitotische kinesin-hemmer
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
ATE494904T1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
ATE248175T1 (de) Epothilonderivate und ihre verwendung als antitumormittel
DE602006008643D1 (de) Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
DE602004010419D1 (de) Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ATE471324T1 (de) Triazolophthalazine
ATE421501T1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
ATE460923T1 (de) Lyophilisierung von virosomen
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
ATE343582T1 (de) Derivate von (6, 7-dihydro -5h-imidazo(1,2 - a)imidazol -3 -sulfonylamino)-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen
DE502005007105D1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü-pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
ATE309701T1 (de) Verwendung von riboflavin und flavinderivaten als inhibitoren von chitinasen